Please login to the form below

Not currently logged in
Email:
Password:

Therakos

This page shows the latest Therakos news and features for those working in and with pharma, biotech and healthcare.

Mallinckrodt pays $1.2bn for Sucampo Pharma

Mallinckrodt pays $1.2bn for Sucampo Pharma

bought Cadence Pharma for $1.3bn, Questcor for $6.5bn, immunotherapy outfit Therakos for $1.3bn and nuclear imaging specialist IBA Molecular for £690m in the last three years.

Latest news

More from news
Approximately 2 fully matching, plus 1 partially matching documents found.

Latest Intelligence

  • Pharma deals in August 2015 Pharma deals in August 2015

    30600. Therakos. Mallinckrodt. Approved cell therapy platform for the palliative treatment of cutaneous T‐cell lymphoma [CTCL].

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
KVA

KVA is an award winning full-service digital communications & brand experience agency. Our healthcare expertise blends creative ‘outside-the-box’ thinking with...

Latest intelligence

Animation: Living With
The journey from the patient's perspective...
Danny Buckland July2022
Achieving communication excellence by targeting the right channel at the right time
By Danny Buckland...
6 trends shaping the future of personalized medicine
Senior Consultant Leah Carlisle explores the key trends discussed at the 16th annual Personalized Medicine Conference, providing expert analysis and key recommendations for biopharmaceutical innovators....